Revaprazan Hydrochloride; Uses, Dosage, Side Effects

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity.It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

Mechanism of Revaprazan Hydrochloride

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

 

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea, but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

……………………information not available & the product goes to under development, or trialing. Further information

References

1. ClinicalTrials.gov

   https://clinicaltrials.gov/

2. Springer Nature

   https://pubchem.ncbi.nlm.nih.gov/substance/341734271

3. Wikipedia

   https://en.wikipedia.org/wiki/Revaprazan

   https://pubchem.ncbi.nlm.nih.gov

4. MeSH

   https://www.ncbi.nlm.nih.gov/mesh/67108798

   http://www.nlm.nih.gov/mesh/meshhome.html